Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Lymphoid 1Head & Neck 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Urinary Bladder Neoplasms 11Prostatic Neoplasms 9Carcinoma, Renal Cell 9Melanoma 4Kidney Neoplasms 3Carcinoma, Transitional Cell 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Testicular Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Colorectal Neoplasms 2Urothelial Cancer 1Sarcoma 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Muscle-invasive Bladder Cancer 1Lymphoma, T-Cell, Cutaneous 1Lung Neoplasms 1Invasive Bladder Cancer 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1

Interventions

Filgrastim 13Carboplatin 10Cyclophosphamide 9pembrolizumab 8Radiosurgery 8Ifosfamide 8Magnetic Resonance Spectroscopy 7Etoposide 7Biopsy 7Specimen Handling 6Doxorubicin 6X-Rays 5Phantoms, Imaging 5Peripheral Blood Stem Cell Transplantation 5Paclitaxel 5Granulocyte Colony-Stimulating Factor 5Gemcitabine 5Cisplatin 5pazopanib 4palbociclib 4Thiotepa 4Temozolomide 4Radiotherapy 4Nuclear Medicine Department, Hospital 4Nivolumab 4Mesna 4Melphalan 4Docetaxel 4Busulfan 4Blood Specimen Collection 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × tremelimumab × Genitourinary × Clear all
NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Ludwig Institute for Cancer Research

Phase 1/2 Completed
58 enrolled 24 charts
BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡